AbbVie updates third quarter 2026 guidance following a $216 million acquired R&D expense

AbbVie announced that its results for the third quarter 2026 will include a $216 million pre-tax charge related to acquired in-process research and development (IPR&D) and milestones. This expense results in a $0.11 per share headwind, leading the company to lower its quarterly and full-year earnings guidance ranges accordingly.

Key Highlights

• Acquired IPR&D and milestones expense for the third quarter totaled $216 million on a pre-tax basis.
• The charges represent an unfavorable impact of $0.11 to both GAAP and adjusted non-GAAP diluted earnings per share.
• Updated third quarter 2026 adjusted diluted EPS guidance range is now $3.73 to $3.77.
• Full-year 2026 adjusted diluted EPS guidance was revised to a range of $13.76 to $13.96.